Overview Fundamentals API Earnings EOD API Sample Code Pricing

Arcus Biosciences Inc (RCUS NYSE) stock market data APIs

$14.51 -0.06(-0.4%) as of July 24, 2024
Price chart is built with Anychart

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences Inc Financial Data Overview

14.57
14.51
-
15.05
14.47
12.95-25.47
1 325 M
90 953 K
237 M
-0.05
0.894
Our easy-to-use no-coding solutions help you get the data effortlessly:

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'RCUS',
Type: 'Common Stock',
Name: 'Arcus Biosciences Inc',
Exchange: 'NYSE',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00DQD26W3',
ISIN: NULL,
CUSIP: NULL,
CIK: '1724521',
EmployerIdNumber: '47-3898435',
FiscalYearEnd: 'December',
IPODate: '2018-03-15',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Arcus Biosciences Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 237 M
  • EBITDA -241 000 000
  • Earnings Per Share -3.11
  • Income Statements
  • Balance Sheets
  • Cash flows
Get sample
of Fundamental API Data

Get Arcus Biosciences Inc Earnings via APIs

  • Latest Release 2024-05-08
  • EPS/Forecast -0.95

Get Arcus Biosciences Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com